



## Metabolomics and/or Biomarkers for Drug Discovery

Guest Editor:

**Prof. Dr. Pollen K. Yeung**

Professor of Pharmacy and  
Medicine, College of Pharmacy,  
Dalhousie University, Halifax, NS  
B3H 4R2, Canada

Deadline for manuscript  
submissions:

**closed (28 February 2018)**

### Message from the Guest Editor

Dear Colleagues,

Metabolomics is the study of biological systems using an integrated approach. It focuses mainly on profiling small-molecule metabolites (metabolic profiling), and differs from genomics and proteomics which characterize the profiles of genes and proteins, respectively. On the other hand, biomarkers are objectively and quantitatively measurable indicators of biological or pathogenic processes. Both metabolomics and biomarkers are increasingly used in drug discovery and development, managing disease progression and personalized medicine. This Special Issue is devoted to the application of metabolomics and/or biomarkers in drug discovery and development. Topics covered by this Special Issue will include (not exclusively): Identification of metabolites and/or biomarkers as targets for drugs and natural health products, validation of targets derived from metabolomics and/or biomarkers, metabolites and/or biomarkers as therapeutics, metabolomics and/or biomarkers for drug development, disease modeling and management, and personalized medicine.

Prof. Dr. Pollen K. Yeung  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Amedeo Lonardo

1. Formerly Director of the Simple Operating Unit "Metabolic Syndrome", Azienda Ospedaliero-Universitaria, 41126 Modena, Italy  
2. Formerly Professor of Internal Medicine, School of Specialization of Allergology and Clinical Immunology, University of Modena and Reggio Emilia, 41121 Modena, Italy

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Biochemistry & Molecular Biology*) / CiteScore - Q2 (*Endocrinology, Diabetes and Metabolism*)

## Contact Us

Metabolites Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/metabolites](http://mdpi.com/journal/metabolites)  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)  
X@MetabolitesMDPI